The UK Brain Monitoring Market was valued at $138.4 Million in 2023 and projected to reach to $204.8 Million by 2028, representing a compound annual growth rate of 8.2%. The UK brain monitoring market is positioned for sustained growth through 2028, supported by NHS commitment to neurology services and increasing clinical adoption of advanced monitoring technologies.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
The UK brain monitoring market is expanding at 8.2% CAGR, outpacing the global rate of 6.3%, driven by NHS investment in neurology services and rising neurological disorder prevalence.
The UK's sophisticated healthcare system and established medical device regulatory framework create a favorable environment for innovative brain monitoring technology adoption and deployment.
Increasing prevalence of conditions such as epilepsy, Parkinson's disease, and dementia across the UK population is driving demand for continuous and non-invasive brain monitoring solutions.
The market is projected to grow from £138.4 million in 2023 to £204.8 million by 2028, representing a 48% increase in market value over the five-year forecast period.
| Report Metric | Details |
|---|---|
| Base Year | 2023 |
| Fastest Growing Segment | CEREBRAL OXIMETERS (Type) |
| Forecast Period | 2023–2028 |
| Growth Rate | CAGR of 6.3% from 2023 to 2028 |
| Largest Segment | NON-INVASIVE PROCEDURES (Procedure) |
| Market Size Base Year (Billions) | ~USD 3.54 (2023) |
| Revenue Forecast (Billions) | ~USD 4.8 (2028) |
| Segments Covered | Product, Type, Usability, Procedure, Modality, Medical Condition, End User |
7 segment dimensions are covered across the global market.
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| AMBULATORY SURGERY CENTERS & CLINICS | 15.9 | 17.4 | 19.4 | 21.3 | 23.4 | 25.6 | 28.1 | 30.7 | 9.6 |
| DIAGNOSTIC CENTRES | 7 | 7.5 | 8.4 | 9.1 | 10 | 10.8 | 11.8 | 12.8 | 8.9 |
| HOSPITALS | 88.7 | 95.4 | 105 | 113.6 | 123.2 | 133 | 143.5 | 154.6 | 8 |
| NEUROLOGICAL CENTRES | 29.6 | 32.4 | 36.4 | 40.1 | 44.3 | 48.8 | 53.7 | 58.9 | 10.1 |
| OTHER END USERS | 12.7 | 13.5 | 14.6 | 15.6 | 16.7 | 17.7 | 18.9 | 20 | 6.5 |
| TOTAL | 153.9 | 166.2 | 183.7 | 199.7 | 217.6 | 236 | 256 | 277.1 | 8.6 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CONMED CORPORATION | United States | Public Company | Orthopedic and Sports Medicine (BioBrace, Y-Knot, Hall power tools, arthroscopy ecosystem),General Surgery (AirSeal, Buffalo Filter, endomechanical, electrosurgery),Endoscopic Technologies and Patient Monitoring, |
| NATUS MEDICAL INCORPORATED | United States | Private Company | Neurodiagnostic systems (EEG, EMG, ICU monitoring, polysomnography, intra-operative monitoring),Newborn care (hearing screening, jaundice management, brain injury, NICU essentials, NICVIEW),Audiology, otoneurologic, and vestibular systems, |
| NIHON KOHDEN CORPORATION | Japan | Public Company | Patient monitors & clinical information systems,Physiological measuring equipment (EEG/ECG/EMG and related),Defibrillators, AEDs, ventilators, anesthesia and related devices, |
| GE HEALTHCARE | United States | Public Company | Imaging,Advanced Visualization Solutions (AVS),Patient Care Solutions (PCS), |
| SIEMENS HEALTHINEERS AG | Germany | Public Company | Imaging,Diagnostics,Varian (Oncology), |
| COMPUMEDICS LIMITED | Australia | Public Company | Sleep diagnostics (PSG, HST, Somfit),Neurology diagnostics (EEG, LTM, ambulatory),Brain research & MEG systems, |
| MEDTRONIC | Ireland | Public Company | Cardiovascular Portfolio,Neuroscience Portfolio,Medical Surgical Portfolio (incl. Surgical, Monitoring, Diabetes), |
| EDWARDS LIFESCIENCES CORPORATION | United States | Public Company | Transcatheter aortic valve replacement (SAPIEN family),Transcatheter mitral and tricuspid (PASCAL, EVOQUE),Surgical structural heart (INSPIRIS, RESILIA, KONECT, MITRIS), |
| CGX | Canada | Public Company | Film Entertainment and Content (theatrical, Event Cinema, food service),Media (on-screen, digital signage, advertising solutions),Location-Based Entertainment (Rec Room, Playdium, Junxion, in-theatre gaming), |
CONMED Corporation is a publicly traded U.S. medical device company founded in 1970 with approximately 3,900 employees.
Natus Medical Incorporated is a U.S.-based private company founded in 1987 with 1,400 employees specializing in medical devices and monitoring solutions.
Nihon Kohden Corporation is a Japanese public company founded in 1951 with 6,116 employees, operating in the medical device and healthcare technology industry.
GE Healthcare is a publicly traded U.S. company established in 2022 with 54,000 employees, providing healthcare technology and solutions.
Siemens Healthineers AG is a German public company with roots dating to 1896 and 72,369 employees, operating as a global leader in medical technology and diagnostics.
Compumedics Limited is an Australian publicly traded company founded in 1987 with 175 employees, specializing in medical device manufacturing.
Medtronic is a publicly traded company founded in Ireland in 1949 with 95,000 employees, serving as a global leader in medical technology and healthcare solutions.
Edwards Lifesciences Corporation is a U.S. public company founded in 1958 with 16,000 employees, specializing in cardiovascular and critical care medical devices.
CGX is a Canadian public company founded in 1912 with 10,000 employees operating across multiple business sectors.
The UK brain monitoring market was valued at £138.4 million in 2023 and is expected to grow to £204.8 million by 2028.
The UK brain monitoring market is projected to grow at a compound annual growth rate (CAGR) of 8.2% from 2023 to 2028.
Wearable devices, portable EEG systems, and non-invasive monitoring solutions are key technologies driving growth in the UK market.
The UK NHS's investment in neurology services and adoption of advanced monitoring technologies across trusts is a major growth driver for the market.
The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating brain monitoring devices in the UK.
The study involved four major activities in estimating the current size of the Brain Monitoring market. Exhaustive secondary research was done to collect information on the market and its different sub-segments. The next step was to validate these findings, assumptions, and market sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of the segments and sub-segments.
This research study involved the extensive usage of secondary sources; directories; databases such as Bloomberg Business, Factiva, and Wall Street Journal; white papers and annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the brain monitoring market. It was also used to obtain important information about the key market players, market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information important for this report. Primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing directors, technology and innovation directors, and related executives from various key companies and organizations operating in the brain monitoring market. After the complete market engineering process (which includes calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at.

*Others include sales managers, marketing managers, and product managers.
Note: Tiers are defined based on a company’s total revenue. As of 2019, Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the Brain Monitoring market. These methods were also used extensively to estimate the size of various subsegments in the market.
The bottom-up procedure was adopted to arrive at the overall size of the Brain Monitoring market from the revenue of key players (companies), their shares in the market, and their annual sales of Brain Monitoring products.

To know about the assumptions considered for the study, Request for Free Sample Report
The overall Brain Monitoring market size was used in the top-down approach to estimate the sizes of other individual markets (mentioned in the market segmentation by product, medical condition, end user, and region) through percentage splits from secondary and primary research.
For the calculation of each type of specific market segment, the most appropriate immediate-parent market size was used for implementing the top-down approach. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained. Market shares were then estimated for top companies to verify the total market revenue arrived earlier in the bottom-up approach.

After arriving at the overall market size, from the market size estimation process explained above, the Brain Monitoring market was split into segments and subsegments. To complete the overall market engineering process and to arrive at the exact statistics for all segments and subsegments, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the Brain Monitoring industry.
Brain Monitoring is a procedure that monitors the activity of various parameters associated with the functioning of brain, which includes electrical activity, blood flow, magnetic activity, the pressure surrounding the brain, and cerebral oxygen saturation.
MarketsandMarkets offers the following customizations for this market report:
Full forecast, segment splits, and company analysis for all Brain Monitoring Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report